SG11202000724XA - Methods and compositions for the treatment of cancer - Google Patents
Methods and compositions for the treatment of cancerInfo
- Publication number
- SG11202000724XA SG11202000724XA SG11202000724XA SG11202000724XA SG11202000724XA SG 11202000724X A SG11202000724X A SG 11202000724XA SG 11202000724X A SG11202000724X A SG 11202000724XA SG 11202000724X A SG11202000724X A SG 11202000724XA SG 11202000724X A SG11202000724X A SG 11202000724XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- compositions
- treatment
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762540901P | 2017-08-03 | 2017-08-03 | |
PCT/US2018/044740 WO2019028098A1 (fr) | 2017-08-03 | 2018-08-01 | Procédés et compositions de traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000724XA true SG11202000724XA (en) | 2020-02-27 |
Family
ID=65234162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000724XA SG11202000724XA (en) | 2017-08-03 | 2018-08-01 | Methods and compositions for the treatment of cancer |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200155600A1 (fr) |
EP (1) | EP3661953A4 (fr) |
JP (1) | JP2020529847A (fr) |
KR (1) | KR20200036874A (fr) |
CN (1) | CN111094328A (fr) |
AU (1) | AU2018308982A1 (fr) |
CA (1) | CA3071448A1 (fr) |
IL (1) | IL272147A (fr) |
SG (1) | SG11202000724XA (fr) |
WO (1) | WO2019028098A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202111081XA (en) * | 2019-04-08 | 2021-11-29 | Taiga Biotechnologies Inc | Compositions and methods for the cryopreservation of immune cells |
CA3137031A1 (fr) * | 2019-05-14 | 2020-11-19 | Yosef Refaeli | Compositions et methodes pour traiter l'epuisement des lymphocytes t |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358739B1 (en) * | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
JP2004528012A (ja) * | 2000-11-01 | 2004-09-16 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改善された免疫応答を誘導し得る発現ベクターおよびこのベクターの使用方法 |
AU2003216288B2 (en) * | 2002-02-13 | 2009-09-24 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
EP1732581A4 (fr) * | 2003-06-20 | 2008-06-04 | Univ California San Diego | Transduction polypeptidique et peptides fusogenes |
US8883507B2 (en) * | 2005-10-18 | 2014-11-11 | The Regents Of The University Of Colorado | Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells |
JP5812861B2 (ja) * | 2008-08-28 | 2015-11-17 | タイガ バイオテクノロジーズ,インク. | Mycの修飾物質、該mycの修飾物質を使用する方法、およびmycを調節する薬剤を同定する方法 |
EP3868387A1 (fr) * | 2012-07-20 | 2021-08-25 | Taiga Biotechnologies, Inc. | Reconstitution et autoreconstitution améliorées du compartiment hématopoïétique |
US9365825B2 (en) * | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
KR20160002971A (ko) * | 2013-04-18 | 2016-01-08 | 틸트 바이오세러퓨틱스 오이 | 향상된 입양 세포 치료 |
US10149898B2 (en) * | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
SG11202000612TA (en) * | 2017-08-03 | 2020-02-27 | Taiga Biotechnologies Inc | Methods and compositions for the treatment of melanoma |
-
2018
- 2018-08-01 KR KR1020207004465A patent/KR20200036874A/ko not_active Application Discontinuation
- 2018-08-01 AU AU2018308982A patent/AU2018308982A1/en active Pending
- 2018-08-01 SG SG11202000724XA patent/SG11202000724XA/en unknown
- 2018-08-01 EP EP18841366.0A patent/EP3661953A4/fr active Pending
- 2018-08-01 US US16/635,383 patent/US20200155600A1/en not_active Abandoned
- 2018-08-01 CN CN201880057363.5A patent/CN111094328A/zh active Pending
- 2018-08-01 CA CA3071448A patent/CA3071448A1/fr active Pending
- 2018-08-01 JP JP2020505464A patent/JP2020529847A/ja active Pending
- 2018-08-01 WO PCT/US2018/044740 patent/WO2019028098A1/fr unknown
-
2020
- 2020-01-20 IL IL272147A patent/IL272147A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20200155600A1 (en) | 2020-05-21 |
WO2019028098A1 (fr) | 2019-02-07 |
IL272147A (en) | 2020-03-31 |
CN111094328A (zh) | 2020-05-01 |
EP3661953A4 (fr) | 2021-04-14 |
CA3071448A1 (fr) | 2019-02-07 |
AU2018308982A1 (en) | 2020-02-13 |
JP2020529847A (ja) | 2020-10-15 |
EP3661953A1 (fr) | 2020-06-10 |
KR20200036874A (ko) | 2020-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268406A (en) | Preparations and methods for treating hemoglobin diseases | |
IL258955A (en) | Preparations and methods for the treatment of cancer | |
IL267247B (en) | Compositions and methods for treating cancer | |
HK1258205A1 (zh) | 用於治療血紅蛋白病的組合物和方法 | |
IL269150A (en) | Preparations and methods for the treatment of cancer | |
IL266053A (en) | Preparations and methods for the treatment of ezh2-mediated cancer | |
IL276808A (en) | Preparations and methods for the treatment of cancer | |
IL268814A (en) | Preparations and methods for the treatment of cancer | |
ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
HK1247630A1 (zh) | 用於增强癌症治療的效果的組合物和方法 | |
IL269157A (en) | Preparations and methods for the treatment of cancer | |
EP3353204A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
IL263793A (en) | Compounds and preparations for the treatment of cancer | |
IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
EP3328372A4 (fr) | Compositions et méthodes de traitement du cancer | |
SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
EP3185910A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP3688023A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
HK1255695A1 (zh) | 用於治療眼瞼下垂的組合物和方法 | |
IL255169A0 (en) | Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer | |
IL272147A (en) | Methods and preparations for the treatment of cancer | |
IL272782A (en) | Preparations and methods for the treatment of cancer | |
EP3681498A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP3515431A4 (fr) | Compositions et méthodes de traitement du cancer |